Media Articles Related to Fluoroplex (Fluorouracil Cutaneous)
Source: MedicineNet Atopic Dermatitis Specialty [2012.06.04]
Title: Keratosis Pilaris
Category: Diseases and Conditions
Created: 8/4/2008 12:00:00 AM
Last Editorial Review: 6/4/2012 12:00:00 AM
Published Studies Related to Fluoroplex (Fluorouracil Cutaneous)
Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in
combination with salicylic acid treating actinic keratoses. 
practicability... CONCLUSIONS: Topical 0.5% 5-FU/SA demonstrated superior sustained clinical
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance
enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line
therapy for metastatic colorectal cancer. 
maintenance therapy for metastatic colorectal cancer (MCRC)... CONCLUSIONS: Enzastaurin combined with bevacizumab-based therapy is tolerable,
Comparison of the efficacy of intralesional triamcinolone acetonide and
5-fluorouracil tattooing for the treatment of keloids. 
for treatment of keloids... CONCLUSION: 5-FU tattooing was more effective than intralesional TAC for the
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion. [2011.11.09]
BACKGROUND: The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT). This study evaluated the efficacy of combined 5-fluorouracil and pegylated interferon (PEG-IFN) alpha-2b in patients with advanced HCC... CONCLUSIONS: Although a prospective randomized controlled trial using a larger population of patients with advanced HCC is needed to evaluate combination therapy with 5-fluorouracil and PEG-IFNalpha-2b, this new combination therapy may be useful for patients with advanced HCC. Cancer 2011;. (c) 2011 American Cancer Society. Copyright (c) 2011 American Cancer Society.
Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. [2011.11]
BACKGROUND: Actinic keratoses (AKs) arise after chronic sun exposure. Because long-term ultraviolet (UV) damage may induce proliferation of atypical keratinocytes, treatment of AKs is recommended. OBJECTIVES: To compare 5-fluorouracil 0.5%/salicylic acid 10.0% [low-dose 5-FU/SA (Actikerall(R))] with diclofenac 3% in hyaluronic acid (diclofenac HA) and vehicle for the treatment of AKs... CONCLUSIONS: Topical low-dose 5-FU/SA demonstrated higher histological and clinical clearance rates vs. diclofenac HA or vehicle. Low-dose 5-FU/SA is an effective lesion-directed treatment for AKs. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists.
Clinical Trials Related to Fluoroplex (Fluorouracil Cutaneous)
A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women [Completed]
To determine the efficacy and safety of intravaginal fluorouracil administered as prophylaxis
in HIV-infected women who have received standard ablative therapy (surgery) for high-grade
cervical dysplasia (pre-cancer of the cervix; cervical intraepithelial neoplasia). To
correlate time to recurrence of cervical dysplasia with T-cell function.
Women with HIV infection are at greater risk for cervical dysplasia. Because of the
likelihood that untreated or recurrent cervical dysplasia may progress to invasive cancer,
there is an urgent need to develop appropriate therapies.
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors [Terminated]
The main purpose of this study is to determine if XL119 is more effective than the
combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of
subjects with advanced biliary tumors.
The Effect of Efudex Treatment on Photoaged Skin [Completed]
The researchers propose that skin improvements may be seen following a course of Efudex,
(5-fluorouracil), a FDA-approved topical therapy (applied directly to the skin). These
improvements could be the result of both a reduction of actinic keratoses (small red horny
growths or flesh-colored wartlike growths caused by overexposure to ultraviolet radiation or
the sun) and improvement of sun-damaged skin.
In addition, this research study is being done to determine if the expression of p53, a tumor
suppressor gene (its activity stops the formation of tumors), is decreased following Efudex
treatment. Mutations (abnormal changes) in the gene, called p53, are associated with a
certain type of skin cancer. In addition, p53-mutated genes are known to exist in
non-cancerous sun-damaged skin. Thus, the presence of p53 mutations may serve as a marker for
both sun damage and an elevated risk of developing skin cancer.
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. [Active, not recruiting]
To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated
with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in
patients with Metastatic Colorectal Cancer.
Definitive Chemoradiation With Gemcitabine and Continuous Fluorouracil (5- FU) Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma [Recruiting]
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment
in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- To establish a preliminary assessment whether toxicity rates are acceptable in patients
with locally advanced intra or extrahepatic cholangiocarcinoma when treated with a
regimen of gemcitabine every two weeks and continuous 5-FU given concurrently with
external beam radiation therapy to a total dose of 45 Gy, followed by a brachytherapy
or Stereotactic Body Radio Therapy (SBRT) boost.
- To evaluate the overall survival rate, progression free survival rate, tumor response
rate, local control rate and the rate of distant metastases following gemcitabine and
continuous 5-FU concurrent with radiation therapy in patients with locally advanced
intra or extrahepatic cholangiocarcinoma.
- To evaluate the rate at which patients with unresectable extrahepatic
cholangiocarcinoma become resectable following gemcitabine and radiation therapy.